GSK plc Fundamental Analysis (XETRA: GS7.DE)
GSK plc (XETRA: GS7.DE) shows moderate financial fundamentals with a PE ratio of 16.17, profit margin of 17.68%, and ROE of 26.11%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 60.2/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze GS7.DE's fundamental strength across five key dimensions:
Efficiency Score
WeakGS7.DE struggles to generate sufficient returns from assets.
Valuation Score
ModerateGS7.DE shows balanced valuation metrics.
Growth Score
ModerateGS7.DE shows steady but slowing expansion.
Financial Health Score
WeakGS7.DE carries high financial risk with limited liquidity.
Profitability Score
ModerateGS7.DE maintains healthy but balanced margins.
Key Financial Metrics
Is GS7.DE Expensive or Cheap?
P/E Ratio
GS7.DE trades at 16.17 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, GS7.DE's PEG of 4.00 indicates potential overvaluation.
Price to Book
The market values GSK plc at 3.98 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -1.98 times EBITDA. This is generally considered low.
How Well Does GS7.DE Make Money?
Net Profit Margin
For every $100 in sales, GSK plc keeps $17.68 as profit after all expenses.
Operating Margin
Core operations generate 23.75 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $26.11 in profit for every $100 of shareholder equity.
ROA
GSK plc generates $6.98 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $1.07 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
16.17
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
4.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.98
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.07
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.79
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.26
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.15
vs 25 benchmark
How GS7.DE Stacks Against Its Sector Peers
| Metric | GS7.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 16.17 | 32.14 | Better (Cheaper) |
| ROE | 26.11% | 550.00% | Weak |
| Net Margin | 17.68% | 30133.00% | Weak |
| Debt/Equity | 1.07 | 0.56 | Weak (High Leverage) |
| Current Ratio | 0.79 | 5.70 | Weak Liquidity |
| ROA | 6.98% | 3.00% | Excellent |
GS7.DE outperforms its industry in 2 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews GSK plc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation